Vitrakvi
Vitrakvi ingredients
| Active ingredient | Strength |
|---|---|
| Larotrectinib | 20 mg/mL, 100 mg/1, 25 mg/1 |
What Vitrakvi is used for
The FDA lists the approved uses on the official label (below). In the EU, larotrectinib is approved as Vitrakvi for:
Vitrakvi as monotherapy is indicated for the treatment of adult and paediatric patients with solid tumours that display a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion, who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and who have no satisfactory treatment options.
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Vitrakvi
- Generic name
- Larotrectinib
- Made by
- Bayer HealthCare Pharmaceuticals Inc.
- Forms
- Capsule, Solution, Solution, Concentrate
- Given
- Oral, Oropharyngeal
- Drug class
- Kinase Inhibitor
- FDA approval
- New drug application (NDA) NDA211710
- On the US market since
- 2018
Official information
- Vitrakvi prescribing information (FDA label) on DailyMed
- MedlinePlus drug information (search for Larotrectinib)
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Vitrakvi?
Vitrakvi (Larotrectinib) is a cancer medicine made by Bayer HealthCare Pharmaceuticals Inc., approved by the US FDA.
What are the ingredients of Vitrakvi?
Vitrakvi contains Larotrectinib (20 mg/mL, 100 mg/1, 25 mg/1).
Is Vitrakvi approved in Europe?
The same active substance is approved in the EU as Vitrakvi.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA